Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company

Piper Jaffray Reiterates Overweight on Mallinckrodt (MNK) Following Solid 1Q Results

February 3, 2016 8:58 AM EST

Piper Jaffray maintained an Overweight rating on Mallinckrodt plc (NYSE: MNK), and cut the price target to $97.00 (from $103.00), following the company's 1Q earnings report. MNK reported revenue and EPS of $915M and $2.09, respectively, compared to the Street's estimates of $889M and $1.78. MNK cautioned that seasonality and deductible resets are likely to be... More